A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
Phase 1
- Conditions
- Overweight, Obesity, Type 2 DiabetesTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2022-502837-24-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1460
Inclusion Criteria
Be overweight or have excess weight., Have history of at least 1 self-reported unsuccessful dietary effort to lose body weight., Have type 2 diabetes and on stable treatment for Type 2 diabetes for at least 90 days prior to screening., Have been taking up to 3 oral anti-hyperglycemic medications
Exclusion Criteria
Have type 1 diabetes or any other type of diabetes except type 2, Have a change in body weight more than 11 pounds within 90 days before screening., Have medullary thyroid cancer or multiple endocrine neoplasia type 2, Have a history of chronic or acute pancreatitis, Have diabetic retinopathy and/or macular edema requiring acute treatment., Have active or untreated cancer for less than 5 years.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method